Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome
Natalizumab may constitute a potential off-label therapeutic for Susac syndrome. Further studies are warranted to assess its efficacy and safety in this rare condition.
Authors
- Gereon R. Fink (ORCID: https://orcid.org/0000-0002-8230-1856)
- Agni Konitsioti (ORCID: https://orcid.org/0000-0002-7296-4349)
- Michael Schroeter (ORCID: https://orcid.org/0000-0001-8441-4793)
- Clemens Warnke (ORCID: https://orcid.org/0000-0002-3510-9255)
- Rafael S. Grajewski (ORCID: https://orcid.org/0000-0001-6489-2982)
- M Schlamann
Institutions
- Philipps University of Marburg (DE)
- Forschungszentrum Jülich (DE)
- University of Cologne (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/ene.70103
- Primary Topic
- Retinal and Optic Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00